



Great Basin Receives CE Mark for Shiga Toxin Direct Test

Standalone molecular test that detects Shiga toxin-producing E. coli (STEC) now available for use outside the United States

Salt Lake City, June 28, 2016 – Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, announced today that its Shiga Toxin Direct Test is available for use outside of the U.S., having earned the CE marking designation under the European Directive on *In Vitro* Diagnostic Medical Devices. The test is now qualified for distribution in more than 32 countries across Europe.

Great Basin's Shiga Toxin Direct Test is the only standalone molecular test approved by the U.S. Food and Drug Administration (FDA), enabling the fast, precise detection of STEC, which are a leading cause of bacterial enteric infections in the U.S. according to the Center of Disease Control (CDC). The CDC has emphasized the importance of appropriate treatment early in the course of STEC infections. In Europe, the European Centre for Disease Prevention and Control (ECDC) and European Food Safety Authority (EFSA) came together just last April to [assess an outbreak of STEC](#), urging EU Member States to intensify their monitoring for the infection. Great Basin's test aids a faster diagnosis and provides laboratory technicians with a streamlined workflow, enabling sample-to-result testing with less than one minute of hands-on time and no specimen enrichment step.

"At a time when outbreaks caused by dangerous bacterial infections like STEC dominate the news, the need for faster identification and detection of the culpable strains and genes to improve clinical outcomes for patients is greater than ever," said Ryan Ashton, co-founder and Chief Executive Officer of Great Basin Scientific. "We look forward to driving new site placements for the Shiga Toxin Direct Test now that we have secured CE Marking, and extending the benefits of our unique, direct-from-patient test to labs and patients beyond the U.S."

The Shiga Toxin Direct Test is the third CE marked molecular diagnostic assay designation for Great Basin, following its tests for Group B *Streptococcus* (GBS) and *Clostridium difficile* (*C. diff*).

About Great Basin Scientific

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company's website at www.gbscience.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding the Company's continuing business efforts related to its products, including but not limited to potential distribution of the Staph ID/R Blood Culture Panel in Europe, planned tests to be brought to clinical trial in 2016 and expansion of the Company's menu. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

Media Contact:

Kate Ottavio Kent

ICR

203.682.8276

Kate.Ottavio-Kent@icrinc.com

Investor Relations Contacts:

Scott Gordon

CorProminence

516.222.2560

gbinfo@corprominence.com

David Clair

ICR

646.277.1266

David.Claire@icrinc.com

###